Edition: Global  
One News Page
“Probably the fastest-access news portal in the world”
> >

Tocagen Expands Toca 5, Phase 2/3 Clinical Trial for Recurrent Brain Cancer, to South Korea

Business Wire Friday, 13 January 2017
Tocagen Expands Toca 5, Phase 2/3 Clinical Trial for Recurrent Brain Cancer, to South KoreaSAN DIEGO--(BUSINESS WIRE)--Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced its randomized, controlled Phase 2/3 clinical trial, called Toca 5, is now enrolling patients in South Korea. The trial is ongoing in the United States, Canada and Israel. The study compares a cancer-selective virus, Toca 511 (vocimagene amiretrorepvec), in combination with Toca FC (extended-release 5-fluorocytosine), to standard of care in patients with first or second recurrence
0
shares
Share on
Facebook
Share on
Twitter
Post on 
Reddit
Share by
Email
 

You Might Like


Recent related news

ADC Therapeutics doses first patient in a phase I clinical trial of ADCT-502 in patients with advanced solid tumors with HER2 expression

EQS Group-News: ADC Therapeutics SA / Key word(s): Study 19.05.2017 / 07:46 -------------------- *ADC Therapeutics Doses First Patient in a Phase...
EQS Group - Press ReleasesAlso reported by •Business WireGlobeNewswire

Minerva Neuroscience prepares to take schizophrenia drug into Phase 3 trials

Minerva Neurosciences Inc. (NASDAQ:NERV) is ready to take MIN-101, a drug targeting negative symptoms in schizophrenia patients, into a pivotal Phase 3 trial....
Proactive Investors - BusinessAlso reported by •GlobeNewswireBusiness Wire

Midatech Pharma selects compound for brain cancer therapy programme

Midatech Pharma Plc (LON:MTPH NASDAQ:MTP) has selected its preferred compound candidate for testing as a potential therapy for glioblastoma (GBM), a rare form of...
Proactive Investors - Business

Targovax ASA: ASCO abstract released

Oslo, Norway, 18 May 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to...
GlobeNewswire - Press Releases

Actinogen Medical begins landmark Alzheimer’s disease clinical trial

Actinogen Medical (ASX:ACW) has reached a major milestone with the first patient treated in XanADu, its Phase II clinical trial of Xanamem in Alzheimer’s...
Proactive Investors - Business

Merus N.V.: Merus Announces Promising Results from MCLA-128 Phase 1/2 Study in Metastatic Breast Cancer

Results to be presented at the 2017 American Society of Clinical Oncology Annual Meeting Phase 2 clinical trial to be initiated in second half of 2017 exploring...
FinanzNachrichten.de - Markets

GlycoMimetics shares surge on positive news on acute myeloid leukemia candidate

GlycoMimetics Inc (NASDAQ: GLYC) shares shot up over 88% to $10.14 as it release positive data on from its ongoing Phase 2 clinical trial of its product...
Proactive Investors - Business

bluebird bio to Present Updated Clinical Results from Novel Anti-BCMA CAR T Cell Therapy bb2121 at American Society of Clinical Oncology (ASCO) Annual Meeting

bluebird bio to Present Updated Clinical Results from Novel Anti-BCMA CAR T Cell Therapy bb2121 at American Society of Clinical Oncology (ASCO) Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies...
Business Wire - Press Releases


Other recent news in Press Releases

Cmed Shows How encapsia® Provides Live, Actionable Data Insights in Oncology Clinical Trials at the 2017 ASCO ANNUAL MEETINGMerkle Named Adobe's Emerging Partner of the Year for the UK, Ireland, Western EUROPE, and the Nordics
Analyzing the $550 Billion Entertainment and Movies Industry in UNITED STATES 2017 - Research and MarketsVolaris Expands in CHICAGO and Los Angeles with New Direct Routes to Querétaro (QRO)
Bella Hadid Debuts a Platinum Necklace at the “Opening Ceremony of the CANNES FILM Festival”Trammell Crow Residential Promotes Jason Ballow to Vice President of Development in the Southern CALIFORNIA Division
Innovus Pharma Signs Exclusive License and Distribution Agreement with Luminarie in AUSTRALIA, New Zealand and the Philippines for Zestra® for Female Sexual Arousal Disorder and Zestra Glide® for Female LubricationPearl Academy’s Students Reimagine MUMBAI through #MUMBAIByDesign
Longines celebrates and awards elegant timepieces for World Approval's victory at Longines Dixie Stakes and Cloud Computing's at PREAKNESS STAKESLONDON Marathon Charitable Trust Launches first national funding programme

Twitter

Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2017 One News Page Ltd. All Rights Reserved.  |  About us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Privacy Policy  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Help  |  Contact us  |  DMCA / Content Removal
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter   FIND us on Google+